FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 267 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Load more HOT NEWS Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... Advanced MRI could help to differentiate aggressive and slower growing prostate... Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in... We have a Deal: What does the new UK-EU relationship mean...
